Jane Street Group LLC Purchases 117,449 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Jane Street Group LLC boosted its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 48.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 360,257 shares of the company's stock after acquiring an additional 117,449 shares during the quarter. Jane Street Group LLC owned 0.30% of 10x Genomics worth $5,173,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC boosted its stake in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after purchasing an additional 1,452 shares in the last quarter. Blue Trust Inc. grew its stake in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after buying an additional 1,299 shares during the last quarter. Sound Income Strategies LLC increased its holdings in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after buying an additional 1,330 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of 10x Genomics in the 4th quarter valued at $52,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of 10x Genomics by 817.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after acquiring an additional 4,324 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Stock Up 2.8 %

Shares of NASDAQ TXG opened at $8.87 on Friday. 10x Genomics, Inc. has a 12-month low of $6.78 and a 12-month high of $28.25. The firm has a market cap of $1.08 billion, a PE ratio of -5.84 and a beta of 1.94. The company's fifty day simple moving average is $8.95 and its 200 day simple moving average is $12.56.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, equities analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TXG has been the topic of a number of recent research reports. Canaccord Genuity Group cut their price target on 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus reduced their target price on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. dropped their price target on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday. Finally, Leerink Partners downgraded 10x Genomics from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $25.00 to $12.00 in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $18.62.

Insider Buying and Selling

In other news, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $56,368.44. Following the completion of the sale, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Benjamin J. Hindson sold 4,573 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the sale, the insider now owns 335,324 shares of the company's stock, valued at $3,712,036.68. This trade represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 9.39% of the stock is owned by company insiders.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.